Overview

  • Product nameAnti-p27 KIP 1 antibody, predilutedSee all p27 KIP 1 primary antibodies ...
  • Description
    Rabbit polyclonal to p27 KIP 1, prediluted
  • Tested applicationsICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) (C terminal)(Human)

  • Positive control
    • MAD109, Prostate and Colon. IF/ICC: A431 cell line

Properties

Applications

Our Abpromise guarantee covers the use of ab15491 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF
IHC-P
  • Application notesIHC-P: Use at an assay dependent dilution. Perform heat mediated antigen retrieval before commencing with IHC staining protocol (for 20min in 0.1% citric acid buffer).

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionImportant regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry.
    • Tissue specificityExpressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney.
    • Involvement in diseaseDefects in CDKN1B are the cause of multiple endocrine neoplasia type 4 (MEN4) [MIM:610755]. Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.
    • Sequence similaritiesBelongs to the CDI family.
    • DomainA peptide sequence containing only AA 28-79 retains substantial Kip1 cyclin A/CDK2 inhibitory activity.
    • Post-translational
      modifications
      Phosphorylated; phosphorylation occurs on serine, threonine and tyrosine residues. Phosphorylation on Ser-10 is the major site of phosphorylation in resting cells, takes place at the G(0)-G(1) phase and leads to protein stability. Phosphorylation on other sites is greatly enhanced by mitogens, growth factors, cMYC and in certain cancer cell lines. The phosphorylated form found in the cytoplasm is inactivate. Phosphorylation on Thr-198 is required for interaction with 14-3-3 proteins. Phosphorylation on Thr-187, by CDK2 leads to protein ubiquitination and proteasomal degradation. Tyrosine phosphorylation promotes this process. Phosphorylation by PKB/AKT1 can be suppressed by LY294002, an inhibitor of the catalytic subunit of PI3K. Phosphorylation on Tyr-88 and Tyr-89 has no effect on binding CDK2, but is required for binding CDK4. Dephosphorylated on tyrosine residues by G-CSF.
      Ubiquitinated; in the cytoplasm by the KPC complex (composed of RNF123/KPC1 and UBAC1/KPC2) and, in the nucleus, by SCF(SKP2). The latter requires prior phosphorylation on Thr-187. Ubiquitinated; by a TRIM21-containing SCF(SKP2)-like complex; leads to its degradation.
      Subject to degradation in the lysosome. Interaction with SNX6 promotes lysosomal degradation.
    • Cellular localizationNucleus. Cytoplasm. Endosome. Nuclear and cytoplasmic in quiescent cells. AKT-or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89. Colocalizes at the endosome with SNX6 and this leads to lysosomal degradation.
    • Information by UniProt
    • Database links
    • Alternative names
      • AA408329 antibody
      • AI843786 antibody
      • Cdki1b antibody
      • CDKN 1B antibody
      • CDKN 4 antibody
      • CDKN1B antibody
      • CDKN4 antibody
      • CDN1B_HUMAN antibody
      • Cyclin Dependent Kinase Inhibitor 1B antibody
      • Cyclin dependent kinase inhibitor p27 antibody
      • Cyclin-dependent kinase inhibitor 1B (p27, Kip1) antibody
      • Cyclin-dependent kinase inhibitor 1B antibody
      • Cyclin-dependent kinase inhibitor p27 antibody
      • Cyclin-dependent kinase inhibitor p27 Kip1 antibody
      • KIP 1 antibody
      • KIP1 antibody
      • MEN1B antibody
      • MEN4 antibody
      • OTTHUMP00000195098 antibody
      • OTTHUMP00000195099 antibody
      • p27 antibody
      • p27 Kip1 antibody
      • P27-like cyclin-dependent kinase inhibitor antibody
      • P27KIP1 antibody
      see all

    Anti-p27 KIP 1 antibody, prediluted images

    • ICC/IF image of ab15491 stained A431 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab15491, Neat) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

    • ab15491 staining p27 KIP 1 in human prostate by Immunohistochemistry (FFPE-sections).

    References for Anti-p27 KIP 1 antibody, prediluted (ab15491)

    This product has been referenced in:
    • Puig I  et al. Deletion of Pten in the mouse enteric nervous system induces ganglioneuromatosis and mimics intestinal pseudoobstruction. J Clin Invest 119:3586-96 (2009). IHC-P ; Mouse . Read more (PubMed: 19884655) »

    See 1 Publication for this product

    Product Wall

    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample Mouse Tissue sections (tumor)
    Specification tumor
    Fixative Formaldehyde
    Antigen retrieval step Heat mediated
    Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 2.5%
    Username

    Dr. Jiqiang Zhang

    Verified customer

    Submitted Nov 09 2005

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"